LeMaitre Vascular Inc
$ 80.82
2.30%
06 Aug - close price
- Market Cap 1,805,208,000 USD
- Current Price $ 80.82
- High / Low $ 82.28 / 79.26
- Stock P/E 39.11
- Book Value 17.80
- EPS 2.02
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.17 %
- 52 Week High 117.72
- 52 Week Low 78.65
About
LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.
Analyst Target Price
$118.75
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-05 | 2026-02-25 | 2025-11-06 | 2025-08-05 | 2025-05-01 | 2025-02-27 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-27 | 2023-11-01 |
| Reported EPS | 0.74 | 0.68 | 0.68 | 0.75 | 0.6 | 0.48 | 0.49 | 0.49 | 0.52 | 0.44 | 0.38 | 0.33 |
| Estimated EPS | 0.81 | 0.66 | 0.66 | 0.56 | 0.57 | 0.5 | 0.49 | 0.43 | 0.47 | 0.39 | 0.36 | 0.3 |
| Surprise | -0.07 | 0.02 | 0.02 | 0.19 | 0.03 | -0.02 | 0 | 0.06 | 0.05 | 0.05 | 0.02 | 0.03 |
| Surprise Percentage | -8.642% | 3.0303% | 3.0303% | 33.9286% | 5.2632% | -4% | 0% | 13.9535% | 10.6383% | 12.8205% | 5.5556% | 10% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | May 2025 | Jan 1970 | Mar 2025 | Dec 2024 | Aug 2024 | May 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-06-04 | 2026-03-26 | 2025-12-04 | 2025-09-04 | 2025-05-29 | None | 2025-03-27 | 2024-12-05 | 2024-08-29 | 2024-05-30 |
| Amount | $0.25 | $0.25 | $0.2 | $0.2 | $0.2 | $0.2 | $0.2 | $0.16 | $0.16 | $0.16 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LMAT
2026-08-06 21:42:06
LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced that its management will participate in investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026. The event will be held in a virtual format. The company specializes in devices and services for peripheral vascular disease.
2026-08-06 17:22:45
LeMaitre Vascular is scheduled to go ex-dividend on August 20th, 2026. The company will be distributing a dividend of $0.25 per share to its shareholders. Investors wishing to receive this dividend should ensure they own shares before the ex-dividend date.
2026-08-06 05:42:45
LeMaitre Vascular (NASDAQ:LMAT) shares hit a new 52-week low after Wells Fargo downgraded its price target and maintained an equal-weight rating, amidst a broader shift in analyst sentiment to "Hold." The company's Q2 revenue and EPS, despite year-over-year growth, missed analyst expectations, leading to a lowered full-year 2026 outlook. Insider sales by CEO George W. Lemaitre and Trent G. Kamke also occurred in May, contributing to the negative sentiment around the stock.
2026-08-05 21:10:20
LeMaitre Vascular (LMAT) stock recently hit a 52-week low at $79.38, despite having a strong 1-year return of nearly 25% and being up over 31% year-to-date. The medical device maker is trading below its Fair Value estimate, with analysts setting price targets between $100 and $135, suggesting potential upside. The recent drop followed second-quarter earnings that, while showing year-over-year growth, missed Wall Street expectations, leading the company to revise its full-year growth outlook downward.
2026-08-05 18:51:00
LeMaitre Vascular Inc. (LMAT) experienced a significant drop of over 22%, trading at $82.06, which would mark its lowest close since January 2026. This decline puts the company on track for its largest percentage decrease since October 2008. The stock is down 30.1% from its all-time high in April 2026, despite being up 1.18% year-to-date.
2026-08-05 16:10:20
Wells Fargo & Company analysts have cut their price target for LeMaitre Vascular (NASDAQ:LMAT) to $94.00 from $104.00, maintaining an "equal weight" rating. This adjustment follows the company's recent earnings report where Q2 EPS of $0.74 missed the consensus estimate of $0.81, and revenue of $70.38 million fell short of expectations. The medical instruments supplier currently has a "Hold" rating from analysts with a consensus price target of $110.60, despite recent downgrades from other firms.
